MCM
PTCT icon

Manchester Capital Management’s PTC Therapeutics PTCT Stock Holding History

Manchester Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-230
Closed -$14.1K – 1456
2025
Q3 		$14.1K Hold
230
– – ﹤0.01% 808
2025
Q2 		$11.2K Hold
230
– – ﹤0.01% 808
2025
Q1 		$11.7K Sell
230
-5
-2% -$250 ﹤0.01% 793
2024
Q4 		$10.6K Hold
235
– – ﹤0.01% 800
2024
Q3 		$8.72K Hold
235
– – ﹤0.01% 823
2024
Q2 		$7.19K Buy
+235
New +$7.61K ﹤0.01% 801

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Manchester Capital Management's PTCT Position: Q4 2025 in Review

Manchester Capital Management sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 230 shares — an estimated $14.1K sold.

Manchester Capital Management first reported a position in PTCT in Q2 2024 and held it in 6 quarters. The position peaked at $14.1K in Q3 2025. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • Manchester Capital Management reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Manchester Capital Management sold 230 PTC Therapeutics shares in Q4 2025, an estimated $14.1K.
  • Manchester Capital Management first reported a position in PTC Therapeutics in Q2 2024 and held it in 6 quarters.
  • Manchester Capital Management's PTC Therapeutics position peaked at $14.1K in Q3 2025.
  • 353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Manchester Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.